Cyclophosphamide therapy for scleroderma.

Abstract

Pulmonary manifestations are the most common cause of death in patients with scleroderma. Consequently, the importance of treatment of both interstital lung disease and pulmonary hypertension has become increasingly evident. Until a placebo-controlled study of any drug has shown its beneficial effect on pulmonary dysfunction, cyclophosphamide may be useful for the treatment of scleroderma lung disease.

• Authors: A Akesson
• Journal: Current opinion in rheumatology (Curr Opin Rheumatol) Vol. 10 Issue 6 Pg. 579-83 (Nov 1998) ISSN: 1040-8711 [Print] United States
• PMID: 9812219 (Publication Type: Journal Article)

Chemical References

• Antirheumatic Agents
• Cyclophosphamide

Topics

• Antirheumatic Agents (adverse effects, therapeutic use)
• Cyclophosphamide (adverse effects, therapeutic use)
• Humans
• Hypertension, Pulmonary (drug therapy, etiology)
• Lung Diseases (drug therapy, etiology)
• Scleroderma, Systemic (complications, drug therapy)